800-845-6913
Tuteur & Associates, LLC | Knowledge is Power.
February 21, 2008
ATLANTA (Associated Press) — Two more studies have found that heart-surgery patients were more likely to die if given the anti-bleeding drug Trasylol, reigniting controversy over the drug’s safety.
Bayer AG suspended sales of the drug last fall, after a Canadian study was halted because of deaths among patients taking Trasylol.
Bayer funded one of the two new studies, and had the preliminary results before a September 2006 federal hearing on the drug’s safety – but did not present them.
The company issued a statement this week saying both new studies were flawed. The spokesman for a consumer-advocacy group said the studies were convincing confirmation of the drug’s dangers.
“I just don’t know how much further evidence you need,” said Sidney Wolfe of Public Citizen’s Health Research Group.
The new studies are being published today in the New England Journal of Medicine.
Continue reading, ‘More Trouble for Trasylol.’